NIPAL3

Summary

NIPAL3 (NIPA like domain containing 3, HGNC:25233) is a protein-coding gene on chromosome 1p36.11, encoding NIPA-like protein 3 (Q6P499).

Predicted to enable magnesium ion transmembrane transporter activity. Predicted to be involved in magnesium ion transport. Predicted to be active in membrane.

Source: NCBI Gene 57185 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 78 total
• MANE Select transcript: NM_020448

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25233
Approved symbol	NIPAL3
Name	NIPA like domain containing 3
Location	1p36.11
Locus type	gene with protein product
Status	Approved
Aliases	DJ462O23.2, SLC57A5
Ensembl gene	ENSG00000001461
Ensembl biotype	protein_coding
OMIM	620034
Entrez	57185

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 16 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000003912, ENST00000339255, ENST00000358028, ENST00000374399, ENST00000432012, ENST00000475663, ENST00000488155, ENST00000869436, ENST00000869437, ENST00000869438, ENST00000869439, ENST00000869440, ENST00000869441, ENST00000869442, ENST00000869443, ENST00000869444, ENST00000869445, ENST00000969634

RefSeq mRNA: 16 — MANE Select: NM_020448 NM_001322854, NM_001322855, NM_001322856, NM_001322857, NM_001322858, NM_001322859, NM_001322860, NM_001322861, NM_001322862, NM_001322863, NM_001322864, NM_001322865, NM_001322866, NM_001322868, NM_001330409, NM_020448

CCDS: CCDS30631, CCDS81280, CCDS81281, CCDS81282

Canonical transcript exons

ENST00000374399 — 12 exons

Exon	Start	End
ENSE00001432973	24415802	24415904
ENSE00001463422	24468986	24472976
ENSE00001603157	24445185	24445244
ENSE00001642364	24456138	24456273
ENSE00001655999	24453408	24453504
ENSE00001679113	24464026	24464120
ENSE00001776100	24449481	24449626
ENSE00003569258	24442055	24442226
ENSE00003575842	24460481	24460544
ENSE00003585417	24419291	24419640
ENSE00003659521	24458888	24458976
ENSE00003670970	24440172	24440240

Expression profiles

Bgee: expression breadth ubiquitous, 276 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.5830 / max 229.6578, expressed in 1754 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1392	10.3044	1727
1391	0.9002	538
1394	0.6933	400
1396	0.4165	150
1393	0.2685	132

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior vagus X ganglion	UBERON:0005363	98.85	gold quality
medial globus pallidus	UBERON:0002477	98.21	gold quality
superior vestibular nucleus	UBERON:0007227	98.14	gold quality
globus pallidus	UBERON:0001875	98.12	gold quality
pons	UBERON:0000988	98.11	gold quality
subthalamic nucleus	UBERON:0001906	98.00	gold quality
ventral tegmental area	UBERON:0002691	97.87	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.71	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.64	gold quality
substantia nigra pars compacta	UBERON:0001965	97.57	gold quality
lateral globus pallidus	UBERON:0002476	97.24	gold quality
parietal lobe	UBERON:0001872	96.47	gold quality
postcentral gyrus	UBERON:0002581	96.34	gold quality
dorsal plus ventral thalamus	UBERON:0001897	96.28	gold quality
corpus callosum	UBERON:0002336	96.19	gold quality
middle temporal gyrus	UBERON:0002771	95.48	gold quality
trigeminal ganglion	UBERON:0001675	95.34	gold quality
medulla oblongata	UBERON:0001896	95.20	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.16	gold quality
entorhinal cortex	UBERON:0002728	94.92	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.74	gold quality
dorsal root ganglion	UBERON:0000044	94.65	gold quality
spinal cord	UBERON:0002240	94.55	gold quality
palpebral conjunctiva	UBERON:0001812	94.52	gold quality
cerebellar cortex	UBERON:0002129	94.50	gold quality
cerebellar hemisphere	UBERON:0002245	94.49	gold quality
superior frontal gyrus	UBERON:0002661	94.28	gold quality
cerebellum	UBERON:0002037	94.15	gold quality
amniotic fluid	UBERON:0000173	94.14	gold quality
endothelial cell	CL:0000115	93.90	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7051	yes	4020.27
E-ANND-3	yes	11.77

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

102 targeting NIPAL3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-4533	100.00	69.48	2758
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-378G	99.71	64.90	1106

Literature-anchored findings (GeneRIF, showing 1)

• Study demonstrates that both human NPAL3 and mouse NPAL3 are ubiquitously expressed and encode highly conserved proteins (PMID:19738379)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nipal3	ENSDARG00000021147
mus_musculus	Nipal3	ENSMUSG00000028803
rattus_norvegicus	Nipal3	ENSRNOG00000037165
drosophila_melanogaster	spict	FBGN0032451
caenorhabditis_elegans		WBGENE00021820

Paralogs (5): NIPAL2 (ENSG00000104361), NIPA2 (ENSG00000140157), NIPAL1 (ENSG00000163293), NIPA1 (ENSG00000170113), NIPAL4 (ENSG00000172548)

Protein

Protein identifiers

NIPA-like protein 3 — Q6P499 (reviewed: Q6P499)

All UniProt accessions (3): A6NN97, Q6P499, H0Y4I9

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

Similarity. Belongs to the NIPA family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6P499-1	1	yes
Q6P499-2	2
Q6P499-3	3

RefSeq proteins (16): NP_001309783, NP_001309784, NP_001309785, NP_001309786, NP_001309787, NP_001309788, NP_001309789, NP_001309790, NP_001309791, NP_001309792, NP_001309793, NP_001309794, NP_001309795, NP_001309797, NP_001317338, NP_065181* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008521	Mg_trans_NIPA	Family

Pfam: PF05653

UniProt features (15 total): transmembrane region 9, splice variant 3, chain 1, modified residue 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P499-F1	74.97	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 372

Glycosylation sites (1): 166

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5223345	Miscellaneous transport and binding events

MSigDB gene sets: 177 (showing top): BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN, GOBP_MAGNESIUM_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP, TCF4_Q5, FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP, KOYAMA_SEMA3B_TARGETS_UP, BROWNE_HCMV_INFECTION_14HR_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, BROWNE_HCMV_INFECTION_24HR_DN, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, DOUGLAS_BMI1_TARGETS_DN, NOUZOVA_METHYLATED_IN_APL, GOBP_TRANSMEMBRANE_TRANSPORT, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN

GO Biological Process (2): magnesium ion transport (GO:0015693), magnesium ion transmembrane transport (GO:1903830)

GO Molecular Function (2): magnesium ion transmembrane transporter activity (GO:0015095), protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion transport	1
magnesium ion transport	1
monoatomic cation transmembrane transport	1
metal ion transmembrane transporter activity	1
magnesium ion transmembrane transport	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

302 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIPAL3	MAGT1	Q9H0U3	789
NIPAL3	SLC41A1	Q8IVJ1	655
NIPAL3	PTP4A2	Q12974	640
NIPAL3	CNNM2	Q9H8M5	619
NIPAL3	CNNM3	Q8NE01	605
NIPAL3	CNNM4	Q6P4Q7	584
NIPAL3	MMGT1	Q8N4V1	575
NIPAL3	TRPM6	Q9BX84	571
NIPAL3	FAM131C	Q96AQ9	527
NIPAL3	CNNM1	Q9NRU3	519
NIPAL3	MRS2	Q9HD23	515
NIPAL3	SLC41A2	Q96JW4	507
NIPAL3	SLC41A3	Q96GZ6	498
NIPAL3	SPRYD7	Q5W111	428
NIPAL3	MAN1C1	Q9NR34	424

IntAct

37 interactions, top by confidence:

A	B	Type	Score
EDA	NIPAL3	psi-mi:“MI:0915”(physical association)	0.830
NIPAL3	EDA	psi-mi:“MI:0915”(physical association)	0.830
NIPAL3	TMEM14B	psi-mi:“MI:0915”(physical association)	0.560
NIPAL3	MFF	psi-mi:“MI:0915”(physical association)	0.560
CD79A	NIPAL3	psi-mi:“MI:0915”(physical association)	0.560
NIPAL3	GPX8	psi-mi:“MI:0915”(physical association)	0.560
NIPAL3	MANBAL	psi-mi:“MI:0915”(physical association)	0.560
VMA21	NIPAL3	psi-mi:“MI:0915”(physical association)	0.560
ATP6V0C	NIPAL3	psi-mi:“MI:0915”(physical association)	0.560
GJA5	NIPAL3	psi-mi:“MI:0915”(physical association)	0.560
NIPAL3	VPS45	psi-mi:“MI:0915”(physical association)	0.560
NIPAL3	VIM	psi-mi:“MI:0915”(physical association)	0.400
NIPAL3	ILVBL	psi-mi:“MI:0914”(association)	0.350
NIPAL4	PGRMC2	psi-mi:“MI:0914”(association)	0.350
NIPAL3	EDA	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	MFF	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	MANBAL	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	VMA21	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	CD79A	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	GPX8	psi-mi:“MI:0915”(physical association)	0.000
NIPAL3	ATP6V0C	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (260): NIPAL3 (Two-hybrid), VPS45 (Affinity Capture-MS), NIPAL3 (Two-hybrid), NIPAL3 (Affinity Capture-MS), MANBAL (Two-hybrid), CD79A (Two-hybrid), TMEM14B (Two-hybrid), EDA (Two-hybrid), VMA21 (Two-hybrid), GPX8 (Two-hybrid), MFF (Two-hybrid), ATP6V0C (Two-hybrid), GJA5 (Two-hybrid), NIPAL3 (Proximity Label-MS), NIPAL3 (Proximity Label-MS)

ESM2 similar proteins: A1L272, A6QL92, B8AF63, E2RFJ3, E7EXX2, O35458, O35633, O54902, O80605, P49281, P49282, P51027, P57057, P58355, Q0VA82, Q28CV2, Q569T7, Q5F383, Q5R6J3, Q5RD30, Q5U3U7, Q62052, Q640L2, Q6DEJ6, Q6DIV6, Q6GPQ3, Q6GQE1, Q6P499, Q6PF45, Q6YK44, Q7RTT9, Q8BGN5, Q8BH31, Q8CBH5, Q8MIQ9, Q8NA29, Q8NBI5, Q8NHS3, Q8R070, Q8R139

Diamond homologs: Q5RD30, Q6P499, Q8BGN5, Q91WC7, Q9H841, Q0D2K0, Q3SWX0, Q5R7Q3, Q8GWX2, Q8GYS1, Q8N8Q9, Q9LIR9, B3LFA3, F4JKQ7, Q5RDB8, Q6NVV3, Q94AH3, Q9LNK7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	58
Likely benign	6
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2436 predictions. Top by Δscore:

Variant	Effect	Δscore
1:24440237:CCAGG:C	donor_loss	1.0000
1:24440238:CAGGT:C	donor_loss	1.0000
1:24440240:GGTA:G	donor_loss	1.0000
1:24440241:G:GG	donor_gain	1.0000
1:24442045:G:A	acceptor_gain	1.0000
1:24442050:TCTA:T	acceptor_loss	1.0000
1:24442051:CTA:C	acceptor_loss	1.0000
1:24442053:A:AG	acceptor_gain	1.0000
1:24442054:G:GA	acceptor_gain	1.0000
1:24442054:GAA:G	acceptor_gain	1.0000
1:24442054:GAAGT:G	acceptor_gain	1.0000
1:24442223:ATAGG:A	donor_loss	1.0000
1:24442224:TAGGT:T	donor_loss	1.0000
1:24442225:AGGTA:A	donor_loss	1.0000
1:24442226:GGTAA:G	donor_loss	1.0000
1:24442227:GTAAG:G	donor_loss	1.0000
1:24442228:TAAGA:T	donor_loss	1.0000
1:24445183:A:AG	acceptor_gain	1.0000
1:24445184:G:GG	acceptor_gain	1.0000
1:24445184:GCTA:G	acceptor_gain	1.0000
1:24445243:GA:G	donor_gain	1.0000
1:24445245:G:GG	donor_gain	1.0000
1:24449625:TGGT:T	donor_loss	1.0000
1:24449627:GT:G	donor_loss	1.0000
1:24449628:T:TC	donor_loss	1.0000
1:24453402:CCACA:C	acceptor_loss	1.0000
1:24453403:CACA:C	acceptor_loss	1.0000
1:24453404:ACAGC:A	acceptor_loss	1.0000
1:24453405:CAG:C	acceptor_loss	1.0000
1:24453406:A:AG	acceptor_gain	1.0000

AlphaMissense

2666 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:24440220:A:C	S48R	0.999
1:24440222:C:A	S48R	0.999
1:24440222:C:G	S48R	0.999
1:24440185:G:A	G36D	0.997
1:24449546:T:C	F154L	0.997
1:24449548:C:A	F154L	0.997
1:24449548:C:G	F154L	0.997
1:24440184:G:C	G36R	0.996
1:24440206:G:A	G43E	0.996
1:24449525:G:C	G147R	0.996
1:24460543:G:T	G309W	0.996
1:24440205:G:A	G43R	0.995
1:24440205:G:C	G43R	0.995
1:24449504:G:C	G140R	0.995
1:24449505:G:A	G140D	0.995
1:24449526:G:A	G147D	0.995
1:24460543:G:A	G309R	0.995
1:24460543:G:C	G309R	0.995
1:24460544:G:A	G309E	0.995
1:24442149:G:A	G86D	0.994
1:24442203:C:G	P104R	0.994
1:24445187:A:C	S113R	0.994
1:24445189:T:A	S113R	0.994
1:24445189:T:G	S113R	0.994
1:24464045:G:C	G316R	0.994
1:24442148:G:C	G86R	0.993
1:24458976:G:C	G288R	0.993
1:24460534:T:C	F306L	0.993
1:24460536:T:A	F306L	0.993
1:24460536:T:G	F306L	0.993

dbSNP variants (sampled 300 via entrez): RS1000040109 (1:24464281 C>T), RS1000129929 (1:24437226 T>G), RS1000143615 (1:24438302 C>G), RS1000154445 (1:24459790 T>A), RS1000183572 (1:24437489 C>G,T), RS1000282600 (1:24457125 G>A,C), RS1000343064 (1:24431489 C>T), RS1000353089 (1:24430390 C>T), RS1000404124 (1:24425436 AATC>A), RS1000435680 (1:24436277 G>A), RS1000443118 (1:24467266 A>G), RS1000517476 (1:24412205 G>T), RS1000552928 (1:24419505 C>T), RS1000631451 (1:24432726 A>G), RS1000639511 (1:24441813 A>G)

Disease associations

OMIM: gene MIM:620034 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006661_57	Male-pattern baldness	4.000000e-09
GCST010302_5	Cutaneous melanoma or hair colour	2.000000e-12
GCST010304_47	Cutaneous malignant melanoma	8.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003924	hair color

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC57 NiPA-like magnesium transporter family

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, affects expression, increases abundance	3
Valproic Acid	affects expression, increases expression	3
sodium arsenite	affects methylation, decreases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
hydroquinone	decreases expression	1
avobenzone	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
entinostat	increases expression	1
abrine	decreases expression	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	increases methylation	1
Cisplatin	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Lead	affects expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression, increases abundance	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4ED	1321N1-NIPAL3-KO-c1	Cancer cell line	Male
CVCL_D4EE	1321N1-NIPAL3-KO-c3	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice